Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.

Elisabetta AntonioliMichela StaderiniSofia PilerciFederico PerfettoFrancesco CappelliMarco AllinoviChiara NozzoliIrene AttucciAlessandra BuzzichelliMaria MesseriAlberto Bosi

Published in: Leukemia & lymphoma (2020)

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
ejection fraction
acute lymphoblastic leukemia
acute myeloid leukemia
prognostic factors
low dose
diffuse large b cell lymphoma
high dose
stem cell transplantation
chronic lymphocytic leukemia